Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...

Of the AT-II-receptor antagonists ... the effects of potent inhibitors of CYP3A4 and CYP2C9 on losartan pharmacokinetics have not been clinically studied. When administered with losartan ...

Valsartan is an angiotensin receptor blocker (“ARB”) that prevents angiotensin II from binding to its receptor, thereby reducing the blood-vessel-constricting effects of angiotensin II ...

Participants with uncontrolled and otherwise treatment-resistant hypertension showed significant blood pressure improvement ...

of six to eight months with camizestrant regardless of the ESR1 status and a benefit over oestrogen receptor blocker fulvestrant in head-to-head data. Roche is petitioning the US administration ...

Inversago is working on peripherally acting CB1 receptor blocker therapies, with the receptor thought to play a role in appetite, and Embark is focused on a potential drug to boost calorie ...

Panelists discuss how immunoglobulin A (IgA) nephropathy treatment has evolved to include supportive care with optimized ...

2023* ACE indicates angiotensin-converting enzyme. This table shows the number of products included in each therapeutic class for generating individual and concurrent reports of prescription fills for ...

This mythbuster has been updated to include an additional search to the medicines usage category that may be used on inspection. This box only lists significant updates, for example where we are ...